Table 1 Main features of the 35 GCA patients at JAKi initiation

Age, years mean ± SD

72.3 ± 8.0

75.6 ± 7.6

67.6 ± 6.3

73.0 ± 8.2

Sex, female/male n (% female)

30/5 (85.7)

14/1 (93.3)

10/0 (100)

6/4 (60)

Time from GCA diagnosis to JAKi initiation (months), median [IQR]

30 [12–48]

32 [12–48]

12 [10.2–45.0]

39 [22.5–75.0]

CLASSIFICATION/DIAGNOSTIC CRITERIA

 Criteria used in the GiACTA trial, n (%)

28 (80)

13 (87)

8 (80)

7 (70)

 ACR 1990, n (%)

21 (60)

7 (47)

6 (60)

8 (80)

GCA PHENOTYPE

 Cranial GCA

15 (43)

6 (17)

4 (40)

5 (50)

 Extracranial GCA

7 (20)

3 (9)

2 (20)

2 (20)

 Mixed GCA

13 (37)

6 (17)

4 (40)

3 (30)

POSITIVE TEMPORAL ARTERY BIOPSY, n (%)

15/24 (62)

6/10 (60)

4/7 (57)

5/7 (71)

POSITIVE IMAGING TECHNIQUE, n (%)

24 (69)

11 (73)

6 (60)

7 (70)

 Ultrasonography, n positive/n performed (% positive)

7/15 (47)

4/9 (44)

1/2 (50)

2/4 (50)

 Positron emission tomography, n positive/n performed (% positive)

16/22 (73)

7/9 (78)

6/7 (86)

3/6 (50)

 Magnetic resonance-angiography, n positive/n performed (% positive)

3/9 (33)

1/2 (50)

1/3 (33)

1/4 (25)

 Computed tomography-angiography, n positive/n performed (% positive)

4/13 (31)

1/3 (33)

1/2 (50)

2/8 (25)

CARDIOVASCULAR RISK FACTORS

 High blood pressure, n (%)

26 (74)

11 (73)

6 (60)

9 (90)

 Dyslipidemia, n (%)

16 (46)

9 (60)

2 (20)

5 (50)

 Diabetes, n (%)

9 (26)

4 (27)

3 (30)

2 (20)

 Previous or current smoking history, n (%)

8 (23)

4 (27)

0 (0)

4 (40)

SYSTEMIC MANIFESTATIONS

 PMR, n (%)

12 (34)

4 (27)

4 (40)

4 (40)

 Constitutional syndrome, n (%)

10 (29)

7 (47)

2 (20)

1 (10)

 Asthenia, n (%)

16 (46)

8 (23)

5 (50)

3 (30)

CRANIAL AND ISCHEMIC MANIFESTATIONS

 Headache, n (%)

15 (43)

7 (47)

5 (50)

3 (30)

 Jaw claudication, n (%)

6 (17)

1 (7)

2 (20)

3 (30)

 Visual symptoms, n (%)

5 (14)

3 (20)

1 (10)

1 (10)

 Stroke, n (%)

2 (6)

1 (7)

1 (0)

0 (0)

LARGE-VESSEL INVOLVEMENT

20 (57)

10 (67)

6 (60)

4 (40)

LABORATORY

 ESR, mm/1st hour, median [IQR]

28 [7–48]

39 [10.5–60.5]

34 [28–48]

7 [2–10]

 CRP, mg/dL, median [IQR]

0.9 [0.4–2.5]

1 [0.4–3.5]

0.9 [0.6-2]

0.7 [0.3–1.8]

 Hb, g/dL, mean ± SD

12.7 ± 1.7

12.4 ± 1.7

12.5 ± 1.4

13.6 ± 2.0

Previous synthetic conventional immunosuppressants use, n (%)

 Methotrexate, n (%)

22 (63)

9 (60)

7 (70)

6 (60)

 Leflunomide, n (%)

1 (3)

0 (0)

1 (10)

0 (0)

 Antimalarials, n (%)

3 (9)

0 (0)

2 (20)

1 (10)

Previous biologic immunosuppressants use, n (%)

 Tocilizumab, n (%)

26 (74)

8 (53)

9 (90)

9 (90)

 Sarilumab, n (%)

3 (9)

2 (13)

0 (0)

1 (10)

 Adalimumab, n (%)

2 (6)

1 (7)

0 (0)

1 (10)

 Abatacept, n (%)

8 (23)

2 (13)

4 (40)

2 (20)

 Ustekinumab, n (%)

2 (6)

0 (0)

1 (10)

1 (10)

GLUCOCORTICOIDS AT JAKi INITIATION

 Patients on prednisone, n (%)

32 (91)

14 (93)

10 (100)

8 (80)

 Prednisone dose, mg/day, median [IQR]

16.2 [8.7–30]

10 [6.2–22.5]

20 [16.2–30]

13.1 [5.6–22.5]